Prevalence and Risk Factors of Pulmonary Hypertension in Patients with Myeloproliferative Neoplasms in Assiut University Hospital.
- Sponsor
- Assiut University
- Study ID
- NCT06647706
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Myeloproliferative Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Transthoracic echocardiography — DEVICEMPNs patients who have echocardiographic probability of PH
Study Details
This study will evaluate the MPNs patients for the presence of PH by using a non invasive method ( Transthoracic echocardiography (TTE )) and correlate the clinical and laboratory data of these patients with development of PH aiming to identify risk factors for PH and parameters that can predict PH in MPNs patients and thus,identifying MPNs patients who require close monitoring \& screening for PH ,hoping that early detection and management of PH in MPNs patients can improve morbidity, prognosis and survival in those patients.
Key Dates
- First listed
- Oct 18, 2024
- Start date
- Nov 1, 2024
- Status verified
- Oct 2024
- Primary completion
- Nov 1, 2025
- Completion
- Dec 1, 2025
Study Design
- Enrollment
- 100 participants (estimated)
Arms
- Arm: MPNs patients who have echocardiographic probability of PHMPNs patients who have echocardiographic probability of PH
- Arm: MPNs patients who do not have echocardiographic probability of PHMPNs patients who do not have echocardiographic probability of PH
Primary Outcome Measure
determine the prevalence of pulmonary hypertension in patients with MPNs at Assiut University Hospital [ Time Frame: 1 year ]
Central Contacts
- Abdelrhman khalaf mohamed, master+2001016901852
- Mohamed Ramadan Abdelhameed, PhD+2001097510010
Related Studies
- Project: Every Child for Younger Patients With CancerRecruiting · Children's Oncology Group · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesPHASE1/PHASE2 · Recruiting · M.D. Anderson Cancer Center · Boston, Massachusetts
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas